Medivation price target raised to $112 from $92 at Maxim Maxim raised its price target for Medivation shares to $112 after extending Xtandi sales projections through 2020. The firm keeps a Buy rating on the stock.
Medivation downgraded to Neutral from Buy at Goldman Goldman Sachs downgraded Medivation to Neutral saying current share levels fairly value Xtandi's opportunities in prostate and breast cancer. Goldman raised its price target for shares to $110 from $90 and believes Medivation's fundamentals remain strong.
Medivation upgraded to Buy at Canaccord As reported previously, Canaccord upgraded Medivation to Buy from Hold citing the pre-chemotherapy opportunity and meaningful incremental share gains of its Xtandi drug. Canaccord raised its price target on Medivation to $132 from $60.